What are the right in­gre­di­ents for a block­buster uni­corn IPO? Nor­bert Bischof­berg­er has some thoughts on that

2020 will stand out in the his­to­ry of biotech for a va­ri­ety of rea­sons, start­ing with the un­prece­dent­ed, rapid-fire re­sponse to Covid-19. But some­where in the top 5 there will be a spe­cial spot­light on the IPO boom, which has been fun­nel­ing bil­lions of dol­lars in­to drug de­vel­op­ment and of­fer­ing some key play­ers a shot at rock star sta­tus — and rock star mon­ey.

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN